PF 6649751

Drug Profile

PF 6649751

Alternative Names: PF-06649751; PF-6649751

Latest Information Update: 26 Apr 2017

Price : $50

At a glance

  • Originator Pfizer
  • Class Antiparkinsonians; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Parkinson's disease

Most Recent Events

  • 07 Apr 2017 Pfizer initiates a phase I trial in Healthy volunteers in USA (NCT03121664)
  • 01 Oct 2016 Phase-II clinical trials in Parkinson's disease in USA (PO, Tablet) (NCT02847650)
  • 25 Jul 2016 Pfizer plans a phase II trial for Parkinson's disease in USA (PO, Tablet) (NCT02847650)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top